# A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

> **NCT03755518** · PHASE3 · TERMINATED · sponsor: **Celgene** · enrollment: 38 (actual)

## Conditions studied

- Primary Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
- Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis

## Interventions

- **DRUG:** FEDRATINIB

## Key facts

- **NCT ID:** NCT03755518
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-27
- **Primary completion:** 2021-11-26
- **Final completion:** 2023-11-08
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Slow accrual.
- **Last updated:** 2024-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755518, "A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03755518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*